Panpan Zhang

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Guanylyl Cyclase 2C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer.

Guanylyl Cyclase 2C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 04, 2026

Long-term control of peritoneal metastases following claudin 18.2-targeted CAR T-Cell therapy in advanced gastric cancer.

Long-term control of peritoneal metastases following claudin 18.2-targeted CAR T-Cell therapy in advanced gastric cancer.

Journal: Journal of hematology & oncology

Published: April 19, 2026

Surufatinib plus toripalimab for patients with advanced solid tumors and disease progression after prior immunotherapy: an open-label multi-cohort phase 2 trial.

Surufatinib plus toripalimab for patients with advanced solid tumors and disease progression after prior immunotherapy: an open-label multi-cohort phase 2 trial.

Journal: Cancer immunology, immunotherapy : CII

Published: February 10, 2026

SMARCA4-deficient thoracic tumors exhibit an immunosuppressive microenvironment and respond to combined antiangiogenic and immune checkpoint inhibitor therapy.

SMARCA4-deficient thoracic tumors exhibit an immunosuppressive microenvironment and respond to combined antiangiogenic and immune checkpoint inhibitor therapy.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 04, 2025

Allogeneic B7-H3-Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study.

Allogeneic B7-H3-Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 03, 2025

The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial.

The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial.

Journal: Nature communications

Published: November 17, 2025

Prognostic and therapeutic roles of specific genotypes through target-gene sequencing on gastroenteropancreatic neuroendocrine carcinoma.

Prognostic and therapeutic roles of specific genotypes through target-gene sequencing on gastroenteropancreatic neuroendocrine carcinoma.

Journal: The oncologist

Published: November 11, 2025

Optimizing CAR T cell therapy for solid tumours: a clinical perspective.

Optimizing CAR T cell therapy for solid tumours: a clinical perspective.

Journal: Nature reviews. Clinical oncology

Published: September 03, 2025

Surufatinib combined with sintilimab and IBI310 for the treatment of high-grade advanced-neuroendocrine neoplasms: A single arm, open-label, single-center, phase II study.

Surufatinib combined with sintilimab and IBI310 for the treatment of high-grade advanced-neuroendocrine neoplasms: A single arm, open-label, single-center, phase II study.

Journal: International journal of cancer

Published: August 07, 2025

Tinengotinib (TT-00420) inhibits tumor growth and overcomes multidrug resistance in gastrointestinal cancers.

Tinengotinib (TT-00420) inhibits tumor growth and overcomes multidrug resistance in gastrointestinal cancers.

Journal: Molecular cancer therapeutics

Published: June 05, 2025

Impact of concomitant medications on efficacy of CLDN18.2-specific CAR-T cell therapy in advanced gastric cancer.

Impact of concomitant medications on efficacy of CLDN18.2-specific CAR-T cell therapy in advanced gastric cancer.

Journal: British journal of cancer

Published: May 29, 2025

Nab-paclitaxel plus bevacizumab for patients with metastatic extrapulmonary neuroendocrine carcinoma: a phase 2 single-arm study.

Nab-paclitaxel plus bevacizumab for patients with metastatic extrapulmonary neuroendocrine carcinoma: a phase 2 single-arm study.

Journal: EClinicalMedicine

Published: May 22, 2025

Showing 1-12 of 50

Last Updated: 09/26/2026